Showing 2 of 10 years of data. Sign up free for 5 years of history.
View Plans2-year trend showing gross, operating, and net profit margins
Zydus Lifesciences Ltd.'s net profit margin of 19.5% in FY2025 reflects good profitability, with operating margin at 24.8% and gross margin at 71.1%.
In FY 2025, Zydus Lifesciences Ltd. posted a gross margin of 71.1%, an operating margin of 24.8%, a net margin of 19.5%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Zydus Lifesciences Ltd.'s revenue grew 18.9% to 232.42B and net profit grew 17.3% to 45.26B YoY in FY2025, indicating healthy business momentum.
In FY 2025, Zydus Lifesciences Ltd.'s revenue grew by 18.9% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Zydus Lifesciences Ltd.'s ROE of 17.2% in FY2025 indicates good shareholder returns.
In FY 2025, Zydus Lifesciences Ltd. reported an ROE of 17.2%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Zydus Lifesciences Ltd.'s FCF/NI ratio of 1.12x in FY2025 indicates solid earnings quality with FCF tracking net income.
In FY 2025, Zydus Lifesciences Ltd.'s free cash flow exceeded net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Zydus Lifesciences Ltd.'s OCF/NI ratio of 1.50x in FY2025 indicates strong cash collection and working capital efficiency.
In FY 2025, Zydus Lifesciences Ltd.'s operating cash flow exceeded net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Zydus Lifesciences Ltd.'s current ratio of 1.89x in FY2025 indicates healthy short-term liquidity.
In FY 2025, Zydus Lifesciences Ltd. reported a current ratio of 1.89. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Zydus Lifesciences Ltd.'s interest coverage ratio of 34.8x in FY2025 indicates comfortable debt servicing capacity.
In FY 2025, Zydus Lifesciences Ltd. reported an interest coverage ratio of 34.8x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Zydus Lifesciences Ltd.'s debt-to-equity ratio of 0.12x in FY2025 reflects a conservative, low-leverage capital structure.
In FY 2025, Zydus Lifesciences Ltd. reported a debt-to-equity ratio of 0.12. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Zydus Lifesciences Ltd.'s debt increased 299.6% YoY in FY2025 — rising leverage demands close monitoring.
In FY 2025, Zydus Lifesciences Ltd.'s total debt increased by 299.6% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Zydus Lifesciences Ltd.'s diluted shares decreased 0.6% YoY in FY2025, indicating shareholder-friendly buybacks.
Over 2 years (FY2024–FY2025), diluted shares decreased 0.6% from 1.01B to 1.01B, reflecting long-term shareholder value creation.
In FY 2025, Zydus Lifesciences Ltd.'s diluted shares decreased by 0.6% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025